Sunday, September 6, 2026
ExploreSearch
Via News
MarketsIndex

S&P 500 Bearish Momentum: 1.48% Down Since The Last Session

ViaNews Editorial Team

January 5, 2021

S&P 500 Bearish Momentum: 1.48% Down Since The Last Session

S&P 500 is currently on bearish momentum. At 09:29 EST on Tuesday, 5 January, S&P 500 is at $3,700.65, 1.48% down since the last session's close.

S&P 500 Range

S&P 500 is 1.036% up from its last session low of $3,662.71 and 1.839% down from its last session high of $3,769.99.

Over the last three sessions, S&P 500's higher value was $3,769.99 and the lower value was $3,662.71.

Over the last seven sessions, S&P 500's higher value was $3,769.99 and the lower value was $3,662.71.

Over the last month, S&P 500's higher value was $3,769.99 and the lower value was $3,633.40.

Regarding S&P 500's yearly highs and lows, it's 0% down from its 52-week low and 0% down from its 52-week high.

Categories

MarketsIndex

Tags

IndexWorld IndicesIndicesSPXS&P 500
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com